Skip to main content
Bret Taback, MD, General Surgery, New York, NY

BretTabackMD

General Surgery New York, NY

Breast, Surgical Oncology (Other than Breast)

Assistant Professor, Surgery, Columbia University College of Phys & Surg

Dr. Taback is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Taback's full profile

Already have an account?

  • Office

    161 Fort Washington Avenue
    New York, NY 10032
    Phone+1 212-305-9676

Education & Training

  • Brown University
    Brown UniversityResidency, Surgery, 1996 - 1999
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Surgery, 1991 - 1994
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1991

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1999 - 2026
  • NY State Medical License
    NY State Medical License 2005 - 2026
  • NJ State Medical License
    NJ State Medical License 2006 - 2025
  • MA State Medical License
    MA State Medical License 1994 - 2011
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Interstitial Laser Ablation as Alternative to Surgical Treatment of Benign Breast Tumors  
    Barbara S Schwartzberg, Bret Taback, Robert Maganini, Kambiz Dowlatshahi, Journal of The American College of Surgeons
  • Predicting Post Neoadjuvant Axillary Response Using a Novel Convolutional Neural Network Algorithm  
    Simukayi Mutasa, Eileen Connolly, Richard Ha, Christine Chin, Bret Taback, Annals of Surgical Oncology

Authored Content

  • Interstitial Laser Ablation as Alternative to Surgical Treatment of Benign Breast TumorsOctober 2018

Press Mentions

  • Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SM
    Impact of Sequencing Targeted Therapies with High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients with Metastatic Renal Cell Carcinoma from an on-Going Observational IL-2 Clinical Trial: PROCLAIM SMFebruary 1st, 2017
  • Annual Meeting Agenda
    Annual Meeting AgendaApril 2nd, 2024

Professional Memberships